Sainte-Foy-lès-Lyon, France
Sainte-Foy-lès-Lyon, France

Time filter

Source Type

PubMed | Center Hospitalier du Pays dAix, Bristol Myers Squibb, HEVA and Estaing University Hospital Center
Type: Journal Article | Journal: Clinics and research in hepatology and gastroenterology | Year: 2016

This retrospective hospital database analysis aimed to determine the burden and cost of hospitalisations related to chronic hepatitis C (CHC) infections in France in 2012.All hospital stays with CHC (ICD-10 code B18.2) coded as the principal, related or significantly associated diagnosis were extracted from the French National Hospital database 2012 (PMSI). Hospitalisations not directly related to CHC were excluded. Patients were assigned to a liver disease stage, namely non-cirrhotic liver disease, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma or post-liver transplantation. Costing was performed using French national tariffs and expressed in 2013 Euros. We documented 22,056 hospital stays involving 12,040 patients who were considered to be directly related to CHC. Of these stays, 11,779 (53.4%) were documented in patients with severe complications (decompensated cirrhosis, hepatocellular carcinoma or liver transplantation).The mean number and duration of hospital stays increased with disease severity. Overall, 1181 patients (9.8%) died during hospitalisation. The total cost of hospital stays for CHC was estimated to be 61 million, of which 26.4% were attributable to hepatocellular carcinoma, 32.5% to post-liver transplantation and 21.0% to decompensated cirrhosis. Compared with a previous analysis in 2009, the number of patients hospitalised fell by 22%, although the patients hospitalised were overall more severely ill. The total cost of hospitalisation decreased by 8%, with a notably marked reduction in the number of biopsies performed (32%). This study illustrates the persistently high burden of CHC infections in France.


News Article | November 8, 2016
Site: www.newsmaker.com.au

Notes: Sales, means the sales volume of AAAA Revenue, means the sales value of AAAA This report studies sales (consumption) of Ethylene Vinyl Acetate (EVA) in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Arkema  LyondellBasell ExxonMobil  Hanwha Celanese Asia Polymer Braskem SA Bridgestone Formosa Plastics Dow Chemical E. I. du Pont de Nemours Eni SpA LANXESS AG Repsol SA Sumitomo ... Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Ethylene Vinyl Acetate (EVA) in these regions, from 2011 to 2021 (forecast), like USA China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Middle EVA (MEVA) Light EVA (LEVA) Heavy EVA (HEVA) Very low EVA (VLEVA) Split by applications, this report focuses on sales, market share and growth rate of Ethylene Vinyl Acetate (EVA) in each application, can be divided into Application 1 Application 2 Application 3 Global Ethylene Vinyl Acetate (EVA) Sales Market Report 2016 1 Ethylene Vinyl Acetate (EVA) Overview 1.1 Product Overview and Scope of Ethylene Vinyl Acetate (EVA) 1.2 Classification of Ethylene Vinyl Acetate (EVA) 1.2.1 Middle EVA (MEVA) 1.2.2 Light EVA (LEVA) 1.2.3 Heavy EVA (HEVA) 1.2.4 Very low EVA (VLEVA) 1.3 Application of Ethylene Vinyl Acetate (EVA) 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Ethylene Vinyl Acetate (EVA) Market by Regions 1.4.1 USA Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Ethylene Vinyl Acetate (EVA) (2011-2021) 1.5.1 Global Ethylene Vinyl Acetate (EVA) Sales and Growth Rate (2011-2021) 1.5.2 Global Ethylene Vinyl Acetate (EVA) Revenue and Growth Rate (2011-2021) 2 Global Ethylene Vinyl Acetate (EVA) Competition by Manufacturers, Type and Application 2.1 Global Ethylene Vinyl Acetate (EVA) Market Competition by Manufacturers 2.1.1 Global Ethylene Vinyl Acetate (EVA) Sales and Market Share of Key Manufacturers (2011-2016) 2.1.2 Global Ethylene Vinyl Acetate (EVA) Revenue and Share by Manufacturers (2011-2016) 2.2 Global Ethylene Vinyl Acetate (EVA) (Volume and Value) by Type 2.2.1 Global Ethylene Vinyl Acetate (EVA) Sales and Market Share by Type (2011-2016) 2.2.2 Global Ethylene Vinyl Acetate (EVA) Revenue and Market Share by Type (2011-2016) 2.3 Global Ethylene Vinyl Acetate (EVA) (Volume and Value) by Regions 2.3.1 Global Ethylene Vinyl Acetate (EVA) Sales and Market Share by Regions (2011-2016) 2.3.2 Global Ethylene Vinyl Acetate (EVA) Revenue and Market Share by Regions (2011-2016) 2.4 Global Ethylene Vinyl Acetate (EVA) (Volume) by Application Figure Picture of Ethylene Vinyl Acetate (EVA) Table Classification of Ethylene Vinyl Acetate (EVA) Figure Global Sales Market Share of Ethylene Vinyl Acetate (EVA) by Type in 2015 Figure Middle EVA (MEVA) Picture Figure Light EVA (LEVA) Picture Figure Heavy EVA (HEVA) Picture Figure Very low EVA (VLEVA) Picture Table Applications of Ethylene Vinyl Acetate (EVA) Figure Global Sales Market Share of Ethylene Vinyl Acetate (EVA) by Application in 2015 Figure Application 1 Examples Figure Application 2 Examples Figure USA Ethylene Vinyl Acetate (EVA) Revenue and Growth Rate (2011-2021) Figure China Ethylene Vinyl Acetate (EVA) Revenue and Growth Rate (2011-2021) Figure Europe Ethylene Vinyl Acetate (EVA) Revenue and Growth Rate (2011-2021) Figure Japan Ethylene Vinyl Acetate (EVA) Revenue and Growth Rate (2011-2021) Figure Global Ethylene Vinyl Acetate (EVA) Sales and Growth Rate (2011-2021) Figure Global Ethylene Vinyl Acetate (EVA) Revenue and Growth Rate (2011-2021) Table Global Ethylene Vinyl Acetate (EVA) Sales of Key Manufacturers (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Sales Share by Manufacturers (2011-2016) Figure 2015 Ethylene Vinyl Acetate (EVA) Sales Share by Manufacturers Figure 2016 Ethylene Vinyl Acetate (EVA) Sales Share by Manufacturers Table Global Ethylene Vinyl Acetate (EVA) Revenue by Manufacturers (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Revenue Share by Manufacturers (2011-2016) Table 2015 Global Ethylene Vinyl Acetate (EVA) Revenue Share by Manufacturers Table 2016 Global Ethylene Vinyl Acetate (EVA) Revenue Share by Manufacturers Table Global Ethylene Vinyl Acetate (EVA) Sales and Market Share by Type (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Sales Share by Type (2011-2016) Figure Sales Market Share of Ethylene Vinyl Acetate (EVA) by Type (2011-2016) Figure Global Ethylene Vinyl Acetate (EVA) Sales Growth Rate by Type (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Revenue and Market Share by Type (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Revenue Share by Type (2011-2016) Figure Revenue Market Share of Ethylene Vinyl Acetate (EVA) by Type (2011-2016) Figure Global Ethylene Vinyl Acetate (EVA) Revenue Growth Rate by Type (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Sales and Market Share by Regions (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Sales Share by Regions (2011-2016) Figure Sales Market Share of Ethylene Vinyl Acetate (EVA) by Regions (2011-2016) Figure Global Ethylene Vinyl Acetate (EVA) Sales Growth Rate by Regions (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Revenue and Market Share by Regions (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Revenue Share by Regions (2011-2016) Figure Revenue Market Share of Ethylene Vinyl Acetate (EVA) by Regions (2011-2016) Figure Global Ethylene Vinyl Acetate (EVA) Revenue Growth Rate by Regions (2011-2016) Table Global Ethylene Vinyl Acetate (EVA) Sales and Market Share by Application (2011-2016) FOR ANY QUERY, REACH US @ Ethylene Vinyl Acetate (EVA) Sales Global Market Research Report 2016


Maravic M.,Hopital Leopold Bellan | Maravic M.,3M | Jouaneton B.,HEVA | Vainchtock A.,HEVA | Tochon V.,Amgen
Clinical and Experimental Rheumatology | Year: 2012

Objectives: To estimate the number and costs of hospitalisations associated with osteoporosis in France. Methods: Data for women aged 50 years and over were extracted from the 2008 French Hospital National Database. Criteria for acute care were established according to ICD-10 codes related to osteoporosis. As coding rules are not systematically used, an additional extraction which included surgical stays for hip fractures was performed in order to be more exhaustive. The two datasets were merged and duplicate stays excluded. Among women hospitalised in acute care during 2008, we selected those progressing to rehabilitation care within the year. We assessed the numbers of hospitalisations and women, proportion of surgical management, length of stay in acute care and numbers of rehabilitation days and costs. Hospital costs were calculated according to the National Hospital Tariff and National Scale of Costs, respectively, for acute and rehabilitation care based on 2009 tariffs. Results: There were 67.807 hospitalisations (64.793 patients) associated with osteoporosis; 83% of total hospitalisations were in patients aged ≥75 years. A total of 80% of hospitalisations were associated with surgical management of fractures and 31.458 patients (49%) progressed from hospitalisation to rehabilitation. The mean ±SD length of stay was 12±8 days for hospitalisation and 43±31 days for rehabilitation care. The overall cost of hospitalisations was 415.4 million, of which 4.2% was related to medical devices. The overall cost of rehabilitation was 331.8 million. Conclusion; In 2008, postmenopausal osteoporosis was associated with a substantial economic burden at hospital in France. © Clinical and Experimental Rheumatology 2012.


Lacau St Guily J.,University Pierre and Marie Curie | Borget I.,Institute Gustave Roussy | Vainchtock A.,HEVA | Remy V.,Sanofi S.A. | Takizawa C.,Sanofi S.A.
Head and Neck Oncology | Year: 2010

Background. With 16,005 new cases and 5,406 related deaths in 2005, France is particularly concerned by Head and Neck (H&N) cancers. In addition to tobacco and alcohol, Human Papillomavirus (HPV) has been reported as a risk factor for H&N cancers. The literature on the burden of these cancers in Europe is scarce. This study was performed to assess the medical and economical burden of hospitalisations for H&N cancers in France. Methods. The French national hospital database (PMSI), in which admissions to public and private hospitals are recorded, was retrospectively analysed to assess the annual number of patients hospitalised for H&N cancers and associated hospital costs from the healthcare payer perspective. ICD-10 codes (16 codes classified as oral cavity, oropharynx, pharynx, salivary glands and larynx) were used to extract admissions for these cancers. Hospital stays, chemotherapy and radiotherapy sessions were extracted to assess patients' management. Costs of admissions were obtained from French official tariffs. Results. In 2007, there were 36 268 patients hospitalised for H&N cancers, of whom 81% were men, corresponding to 60 200 hospital stays and 287 846 sessions of chemo- or radio-therapy. Oropharynx cancer was the most frequent (28% of patients), followed by oral cavity cancer (25% of patients). The peak of frequency was observed in the 55-59 years age group. Patients were mainly treated in medicine (48%) and surgery (23%) units. Mean annual cost per patient ranged from 2 764 to 7 673 leading to a total hospital cost of 323 millions in 2007 (including hospitalization and expensive drugs). With 26% of H&N cancers attributable to HPV infections, 9 430 patients were hospitalized due to HPV-related H&N cancers, representing 138 million in 2007. Conclusion. Even without taking into account the rehabilitation costs, the hospital burden of H&N cancers is considerable. © 2010 St Guily et al; licensee BioMed Central Ltd.


Blein C.,HEVA | Gavazzi G.,Grenoble University Hospital Center | Paccalin M.,University of Poitiers | Baptiste C.,Sanofi S.A. | And 2 more authors.
BMC Infectious Diseases | Year: 2015

Background: The objectives of this study were to describe hospital stays related to HZ and to evaluate the direct and indirect cost of hospitalizations due to HZ among patients aged over 50 years. Methods: The hospitalizations of people aged over 50 years were selected from the French national hospital 2011 database (PMSI) using ICD-10 diagnosis codes for HZ. Firstly, stays with HZ as principal or related diagnostic were described through the patient characteristics, type of hospitalization and the related costs. Secondly, a retrospective case-control analysis was performed on stays with HZ as comorbidity in 5 main hospitalizations causes (circulatory, respiratory, osteo-articular, digestive systems and diabetes) to assess the impact of HZ as co-morbidity on the length of stay, mortality rate and costs. Results: In the first analysis, 2,571 hospital stays were collected (60 % of women, mean age: 76.3 years and mean LOS: 9.5 days). The total health assurance costs were 10,8 M€. Mean cost per hospital stay was 4,206€. In the second analysis, a significant difference in LOS and costs was shown when HZ was associated as comorbidity in other hospitalization's causes. Conclusions: HZ directly impacts on the hospital cost. When present as comorbidity for other medical reasons, HZ significantly increases the length of hospital stay with subsequent economic burden for the French Health System. © 2015 Blein et al.


Marty R.,HEVA | Roze S.,HEVA | Bresse X.,SPMSD SNC | Largeron N.,SPMSD SNC | Smith-Palmer J.,Ossian Health Economics and Communications
BMC Cancer | Year: 2013

Background: HPV is related to a number of cancer types, causing a considerable burden in both genders in Europe. Female vaccination programs can substantially reduce the incidence of HPV-related diseases in women and, to some extent, men through herd immunity. The objective was to estimate the incremental benefit of vaccinating boys and girls using the quadrivalent HPV vaccine in Europe versus girls-only vaccination. Incremental benefits in terms of reduction in the incidence of HPV 6, 11, 16 and 18-related diseases (including cervical, vaginal, vulvar, anal, penile, and head and neck carcinomas and genital warts) were assessed.Methods: The analysis was performed using a model constructed in Microsoft®Excel, based on a previously-published dynamic transmission model of HPV vaccination and published European epidemiological data on incidence of HPV-related diseases. The incremental benefits of vaccinating 12-year old girls and boys versus girls-only vaccination was assessed (70% vaccine coverage were assumed for both). Sensitivity analyses around vaccine coverage and duration of protection were performed.Results: Compared with screening alone, girls-only vaccination led to 84% reduction in HPV 16/18-related carcinomas in females and a 61% reduction in males. Vaccination of girls and boys led to a 90% reduction in HPV 16/18-related carcinomas in females and 86% reduction in males versus screening alone. Relative to a girls-only program, vaccination of girls and boys led to a reduction in female and male HPV-related carcinomas of 40% and 65%, respectively and a reduction in the incidence of HPV 6/11-related genital warts of 58% for females and 71% for males versus girls-only vaccination.Conclusions: In Europe, the vaccination of 12-year old boys and girls against HPV 6, 11, 16 and 18 would be associated with substantial additional clinical benefits in terms of reduced incidence of HPV-related genital warts and carcinomas versus girls-only vaccination. The incremental benefits of adding boys vaccination are highly dependent on coverage in girls. Therefore, further analyses should be performed taking into account the country-specific situation. In addition to clinical benefits, substantial economic benefits are also anticipated and warrant further investigation as do the social and ethical implications of including boys in vaccination programs. © 2013 Marty et al.; licensee BioMed Central Ltd.


Bresse X.,SP MSD SNC | Adam M.,SP MSD SNC | Largeron N.,SP MSD SNC | Roze S.,HEVA | Marty R.,HEVA
Human Vaccines and Immunotherapeutics | Year: 2013

The aim was to compare the epidemiological and economic impact of bivalent HPV 16/18 and quadrivalent HPV 6/11/16/18 vaccinations in France, considering differences in licensed outcomes, protection against non-vaccine HPV types and prevention of HPV-6/11-related diseases. The differential impact of the two vaccines was evaluated using a published model adapted to the French setting. The target population was females aged 14-23 y and the time horizon was 100 y. A total of eight different scenarios compared vaccination impact in terms of reduction in HPV-16/18-associated carcinomas (cervical, vulvar, vaginal, anal, penile and head and neck), HPV-6/11-related genital warts and recurrent respiratory papillomatosis, and incremental reduction in cervical cancer due to potential cross-protection. Quadrivalent vaccine was associated with total discounted cost savings ranging from EUR 544-1,020 million vs. EUR 177-538 million with the bivalent vaccination (100-y time horizon). Genital warts prevention thanks to quadrivalent HPV vaccination accounted for EUR 306-380 million savings (37-56% of costs saved). In contrast, the maximal assumed crossprotection against cervical cancer resulted in EUR 13-33 million savings (4%). Prevention of vulvar, vaginal and anal cancers accounted for additional EUR 71-89 million savings (13%). In France, the quadrivalent HPV vaccination would result in significant incremental epidemiological and economic benefits vs. the bivalent vaccination, driven primarily by prevention of genital warts. The present analysis is the first in the French setting to consider the impact of HPV vaccination on all HPV diseases and non-vaccine types. © 2013 Landes Bioscience.


Marty R.,Ipsen | Roze S.,Ipsen | Kurth H.,HEVA
Medical Devices: Evidence and Research | Year: 2012

Background: Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and neuroendocrine tumors. A simple decision-tree model aimed at comparing cost savings with ready-to-use Somatuline Autogel® (lanreotide) and Sandostatin LAR® (octreotide) for the UK, France, and Germany. The drivers of cost savings studied were the reduction of time to administer as well as a reduced baseline risk of clogging during product administration reported for Somatuline Autogel®. Methods: The decision-tree model assumed two settings for SRL administration, ie, by either hospital-based or community-based nurses. In the case of clogging, the first dose was assumed to be lost and a second injection performed. Successful injection depended on the probability of clogging. Direct medical costs were included. A set of scenarios were run, varying the cost drivers, such as the baseline risk of clogging, SRL administration time, and percentage of patients injected during a hospital stay. Results: Costs per successful injection were less for Somatuline Autogel® /Depot, ranging from Euros (EUR) 13-45, EUR 52-108, and EUR 127-151, respectively, for France, Germany, and the UK. The prices for both long-acting SRL were the same in France, and cost savings came to 100% from differences other than drug prices. For Germany and the UK, the proportion of savings due to less clogging and shorter administration time was estimated to be around 32% and 20%, respectively. Based on low and high country-specific patient cohort size estimations of individuals eligible for SRL treatment among the patient population with acromegaly and neuro endocrine tumors, annual savings were estimated to be up to EUR 2,000,000 for France, EUR 6,000,000 for Germany, and EUR 7,000,000 for the UK. Conclusion: This model suggests that increasing usage of the Somatuline device for injection of SRL might lead to substantial savings for health care providers across Europe. © 2012 Marty et al, publisher and licensee Dove Medical Press Ltd.


Cotte F.-E.,Bristol Myers Squibb | Chaize G.,HEVA | Kachaner I.,Pfizer | Gaudin A.-F.,Bristol Myers Squibb | And 2 more authors.
Journal of Stroke and Cerebrovascular Diseases | Year: 2014

Background Stroke represents a major complication of atrial fibrillation (AF). The current anticoagulation options for stroke prevention increase hemorrhage risk. The objective of the study was to estimate the incidence and costs of hospitalization for stroke and hemorrhage in patients with AF who are eligible for stroke prevention. Methods Patients hospitalized for AF were identified from the French National hospital database (Programme Médicalisé des Systèmes d'Information) and a calculated stroke risk score (congestive heart failure, hypertension [blood pressure consistently >140/90 mm Hg], age ≥75 years, diabetes mellitus, and previous stroke, transient ischemic attack [CHADS2]). Adult patients eligible for stroke prevention (CHADS2 >0) were enrolled. The incidence of hospitalization for stroke and hemorrhage was calculated over a 2-year period. Costs of acute care were determined using diagnosis related groups (DRGs) and corresponding National Hospital Tariffs. Rehabilitation costs were analyzed for patients with strokes and classified by stroke severity. Results Sixty-one thousand five hundred eighty-two patients were identified with a mean age of 75.0 ± 11.0 years and a mean CHADS2 score of 1.90 ± 0.99. The 24-month cumulative incidence of any stroke was 32.1 cases/1,000 patients with AF (ischemic, 60%; hemorrhagic, 24%; unspecified, 16%), and that of hemorrhage was 53.1 cases/1,000 patients with AF (gastrointestinal, 26%; intracranial, 5%; other, 69%). The mean costs of ischemic and hemorrhagic strokes were €4,848 and €7,183 (mild), €10,909 and €14,298 (moderate), €29,065 and €29,701 (severe), and €6,035 and €4,590 (fatal), respectively. The mean costs of hemorrhage by type were €3,601 (gastrointestinal), €7,331 (intracranial), €3,941 (other major), and €2,552 (nonmajor). Conclusions The incidence and cost of hospitalization for hemorrhage should be considered in the global burden of AF. These data should be useful for pharmacoeconomic evaluation of new oral anticoagulant medications. Such real-world studies may be relevant for monitoring mid- to long-term morbidity and mortality in the AF population. © 2014 by National Stroke Association.


PubMed | University of Tours, Bristol Myers Squibb, University of Massachusetts Medical School and HEVA
Type: | Journal: International journal of cardiology | Year: 2016

The HAS-BLED, ATRIA, and HEMORR2HAGES risk scores were created to evaluate individual bleeding risk in atrial fibrillation (AF). We sought to estimate and compare the predictive ability of these scores for major hemorrhage in AF, including elderly (80years) and non-elderly (<80years) patients.This cross-sectional study is based on the French National Hospital Database (PMSI), which covers the entire French population. Data from all patients with an AF diagnosis in 2012 were extracted. Demographic and comorbidity data were used to calculate the three bleeding risk scores for each patient. Patients hospitalized with a principal diagnosis of major bleeding were identified.Of the 533,044 AF patients identified, 53.2% were 80years; 7013 patients (1.3%) were hospitalized for a bleeding event (1785 for intracranial hemorrhage). Bleeding occurred more frequently in patients with higher HAS-BLED, HEMORR2HAGES, and ATRIA scores. In patients 80years, the c-statistics did not differ (p=0.27) between HAS-BLED (0.54; 95% confidence interval [CI]: 0.53-0.54), HEMORR2HAGES (0.53; 95% CI: 0.53-0.54), and ATRIA (0.53; 95% CI: 0.52-0.54). In patients <80years, HAS-BLED (0.59; 95% CI: 0.58-0.60) had a slightly higher c-statistic than HEMORR2HAGES (0.56; 95% CI: 0.55-0.57) and ATRIA (0.55, 95% CI: 0.55-0.56) (p<0.0001).Given its simplicity and similar performance, HAS-BLED may be an attractive alternative to HEMORR2HAGES for estimation of bleeding risk in AF patients <80years. However, accurate determination of bleeding risk among the elderly is difficult with existing risk-prediction scores, indicating a clear need for improvement in their clinical utility.

Loading HEVA collaborators
Loading HEVA collaborators